OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA

Authors :: J. Yan
S. Meadows-Shropshire
David P. Carbone
Manuel Cobo Dols
Tudor-Eliade Ciuleanu
Arnaud Scherpereel
M. Schenker
A. Alexandru
Hiroshi Sakai
Eduardo Richardet
Shunyuan Lu
Luis Paz-Ares
Thomas John
Martin Reck
B. Zurawski
J. Menezes
Jaafar Bennouna
Enriqueta Felip
Oscar Juan Vidal
Source :: Journal of Thoracic Oncology. 16:S2
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Chemotherapy
business.industry
First line
medicine.medical_treatment
Checkmate
Ipilimumab
Recurrent Non-Small Cell Lung Cancer
Internal medicine
Medicine
Nivolumab
Stage iv
business
medicine.drug

Full Text Access

Tools